GTBP Share Price Performance
US$1.78
-0.55 (-23.61%)
Price US$1.78
Share PriceUS$1.78
GTBP Community Narratives
There are no narratives available yet.
Recent GTBP News & Updates
No updates
GT Biopharma, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.71
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
GT Biopharma, Inc. Competitors
About GTBP
- Founded
- 1965
- Employees
- 1
- CEO
- WebsiteView website
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 23% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading